An integrated approach for characterizing immunogenic responses toward a bispecific antibody

References

• Spiess C, Zhai Q, Carter PJ. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol. 2015;67:95–10. doi:10.1016/j.molimm.2015.01.003.
   PubMed Web of Science ®Google Scholar
• Li H, Saw PE, Song E. Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics. Cell Mol Immunol. 2020;17:451–61. doi:10.1038/s41423-020-0417-8.
   PubMed Web of Science ®Google Scholar
• Huang S, van Duijnhoven SM, Sijts AJ, van Elsas A. Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy. J Cancer Res Clin Oncol. 2020;146:1–12. doi:10.1007/s00432-019-03068-x.
   PubMed Web of Science ®Google Scholar
• Nie S, Wang Z, Moscoso-Castro M, D’Souza P, Lei C, Xu J, Gu J. Biology drives the discovery of bispecific antibodies as innovative therapeutics. Antibody Ther. 2020;3:18–62. doi:10.1093/abt/tbaa003.
   PubMedGoogle Scholar
• Talotta R, Rucci F, Canti G, Scaglione F. Pros and cons of the immunogenicity of monoclonal antibodies in cancer treatment: a lesson from autoimmune diseases. Immunotherapy. 2019;11(3):241–54. doi:10.2217/imt-2018-0081.
   PubMed Web of Science ®Google Scholar
• Staton TL, Peng K, Owen R, Choy DF, Cabanski CR, Fong A, Brunstein F, Alatsis KR, Chen H. A phase I, randomized, observer-blinded, single and multiple ascending-dose study to investigate the safety, pharmacokinetics, and immunogenicity of BITS7201A, a bispecific antibody targeting IL-13 and IL-17, in healthy volunteers. BMC Pulm Med. 2019;19:1–16. doi:10.1186/s12890-018-0763-9.
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Bivi N, Calderon B, Shimizu T, Delafontaine B, Liu ZT, Szpurka AM, Copeland V, Hodi FS, Rottey S, et al. Safety and Immunogenicity of LY3415244, a bispecific antibody against TIM-3 and PD-L1, in patients with advanced solid tumors. Clin Cancer Res. 2021;27(10):2773–81. doi:10.1158/1078-0432.CCR-20-3716.
   PubMed Web of Science ®Google Scholar
• Paz-Priel I, Chang T, Asikanius E, Chebon S, Emrich T, Fernandez E, Kuebler P, Schmitt C. Immunogenicity of emicizumab in people with hemophilia A (PwHA): results from the HAVEN 1-4 studies. Blood. 2018;132(Supplement 1):633. doi:10.1182/blood-2018-99-118492.
   Google Scholar
• Sampei Z, Igawa T, Soeda T, Okuyama-Nishida Y, Moriyama C, Wakabayashi T, Tanaka E, Muto A, Kojima T, Kitazawa T, et al. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PloS One. 2013;8(2):e57479. doi:10.1371/journal.pone.0057479.
   PubMed Web of Science ®Google Scholar
• De Groot AS, McMurry J, Moise L. Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates. Curr Opin Pharmacol. 2008;8:620–26. doi:10.1016/j.coph.2008.08.002.
   PubMed Web of Science ®Google Scholar
• Brinkmann U, Kontermann RE. The making of bispecific antibodies. MAbs: Taylor & Francis. 2017;9(2):182–212. doi:10.1080/19420862.2016.1268307.
   PubMed Web of Science ®Google Scholar
• Klein C, Schaefer W, Regula JT, Dumontet C, Brinkmann U, Bacac M, Umaña P. Engineering therapeutic bispecific antibodies using CrossMab technology. Methods. 2019;154:21–31. doi:10.1016/j.ymeth.2018.11.008.
   PubMed Web of Science ®Google Scholar
• Sedykh SE, Prinz VV, Buneva VN, Nevinsky GA. Bispecific antibodies: design, therapy, perspectives. Drug Des Devel Ther. 2018;12:195. doi:10.2147/DDDT.S151282.
   PubMed Web of Science ®Google Scholar
• Atwell S, Ridgway JB, Wells JA, Carter P. Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. J Mol Biol. 1997;270:26–35. doi:10.1006/jmbi.1997.1116.
   PubMed Web of Science ®Google Scholar
• Ridgway JB, Presta LG, Carter P. ‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng Des Sel. 1996;9:617–21. doi:10.1093/protein/9.7.617.
   Google Scholar
• Spiess C, Merchant M, Huang A, Zheng Z, Yang N-Y, Peng J, Ellerman D, Shatz W, Reilly D, Yansura DG, et al. Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies. Nat Biotechnol. 2013;31:753–58. doi:10.1038/nbt.2621.
   PubMed Web of Science ®Google Scholar
• Peng K, Siradze K, Fischer SK. Characterization of robust immune responses to a bispecific antibody, a novel class of antibody therapeutics. Bioanalysis. 2021;13:239–52. doi:10.4155/bio-2020-0281.
   PubMed Web of Science ®Google Scholar
• Jensen KK, Andreatta M, Marcatili P, Buus S, Greenbaum JA, Yan Z, Sette A, Peters B, Nielsen M. Improved methods for predicting peptide binding affinity to MHC class II molecules. Immunology. 2018;154:394–406. doi:10.1111/imm.12889.
   PubMed Web of Science ®Google Scholar
• Greenbaum J, Sidney J, Chung J, Brander C, Peters B, Sette A. Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes. Immunogenetics. 2011;63:325–35. doi:10.1007/s00251-011-0513-0.
   PubMed Web of Science ®Google Scholar
• Ito S, Ikuno T, Mishima M, Yano M, Hara T, Kuramochi T, Sampei Z, Wakabayashi T, Tabo M, Chiba S, et al. In vitro human helper T-cell assay to screen antibody drug candidates for immunogenicity. J Immunotoxicol. 2019;16:125–32. doi:10.1080/1547691X.2019.1604586.
   PubMed Web of Science ®Google Scholar
• Welt S, Ritter G, Williams C, Cohen LS, John M, Jungbluth A, Richards EA, Old LJ, Kemeny NE. Phase I study of anticolon cancer humanized antibody A33. Clin Cancer Res. 2003;9:1338–46.
   PubMed Web of Science ®Google Scholar
• Ulitzka M, Carrara S, Grzeschik J, Kornmann H, Hock B, Kolmar H. Engineering therapeutic antibodies for patient safety: tackling the immunogenicity problem. Protein Eng Des Sel. 2020;33. doi:10.1093/protein/gzaa025.
   PubMed Web of Science ®Google Scholar
• Dingman R, Balu-Iyer SV. Immunogenicity of protein pharmaceuticals. J Pharm Sci. 2019;108:1637–54.
   PubMed Web of Science ®Google Scholar
• Fu K, March K, Alexaki A, Fabozzi G, Moysi E, Petrovas C. Immunogenicity of Protein Therapeutics: a Lymph Node Perspective. Front Immunol. 2020;11:11. doi:10.3389/fimmu.2020.00791.
   PubMed Web of Science ®Google Scholar
• Lu Y, Khawli LA, Purushothama S, Theil F-P, Partridge MA. Recent advances in assessing immunogenicity of therapeutic proteins: impact on biotherapeutic development. J Immunol Res. 2016;2016.
   Web of Science ®Google Scholar
• Hidalgo M, Martinez-Garcia M, Le Tourneau C, Massard C, Garralda E, Boni V, Taus A, Albanell J, Sablin M-P, Alt M, et al. First-in-human phase I study of single-agent vanucizumab, a first-in-class bispecific anti-angiopoietin-2/anti-VEGF-A antibody, in adult patients with advanced solid tumors. Clin Cancer Res. 2018;24(7):1536–45. doi:10.1158/1078-0432.CCR-17-1588.
   PubMed Web of Science ®Google Scholar
• Reynisson B, Alvarez B, Paul S, Peters B, Nielsen M. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res. 2020;48(W1):W449–W54. doi:10.1093/nar/gkaa379.
   PubMed Web of Science ®Google Scholar
• Schneidman-Duhovny D, Khuri N, Dong GQ, Winter MB, Shifrut E, et al. Predicting CD4 T-cell epitopes based on antigen cleavage, MHCII presentation, and TCR recognition. PloS One. 2018;13:e0206654. doi:10.1371/journal.pone.0206654.
   PubMed Web of Science ®Google Scholar
• Reche P, Flower DR, Fridkis-Hareli M, Hoshino Y. Peptide-based immunotherapeutics and vaccines 2017. J Immunol Res. 2018 Jul 15;2018:4568239. doi: 10.1155/2018/4568239. PMID: 30116752; PMCID: PMC6079504.
   Google Scholar
• Kovalova N, Knierman MD, Brown-Augsburger PL, Wroblewski VJ, Chlewicki LK. Correlation between antidrug antibodies, pre-existing antidrug reactivity, and immunogenetics (MHC class II alleles) in cynomolgus macaque. Immunogenetics. 2019;71:605–15. doi:10.1007/s00251-019-01136-7.
   PubMed Web of Science ®Google Scholar
• van Meer PJ, Kooijman M, Brinks V, Gispen-de Wied CC, Silva-Lima B, et al. Immunogenicity of mAbs in non-human primates during nonclinical safety assessment. MAbs: Taylor & Francis. pp.810–16. 2013. doi:10.4161/mabs.25234
   Google Scholar
• De Groot AS, Moise L, Terry F, Gutierrez AH, Hindocha P, Richard G, Hoft DF, Ross TM, Noe AR, Takahashi Y, et al. Better epitope discovery, precision immune engineering, and accelerated vaccine design using immunoinformatics tools. Front Immunol. 2020;11:442. doi:10.3389/fimmu.2020.00442.
   PubMed Web of Science ®Google Scholar
• Peng K, Siradze K, Quarmby V, Fischer SK. Clinical immunogenicity specificity assessments: a platform evaluation. J Pharm Biomed Anal. 2011;54:629–35. doi:10.1016/j.jpba.2010.09.035.
   PubMed Web of Science ®Google Scholar
• FDA.gov. Center for drug evaluation and research. Immunogenicity testing of therapeutic protein products —Developing and validating assays for anti-drug antibody detection. 2019. accessed 2021 Mar 8. https://wwwfdagov/regulatory-information/search-fda-guidance-documents/immunogenicity-testing-therapeutic-protein-products-developing-and-validating-assays-anti-drug
   Google Scholar
• Shankar G, Devanarayan V, Amaravadi L, Barrett YC, Bowsher R, Finco-Kent D, Fiscella M, Gorovits B, Kirschner S, Moxness M, et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal. 2008;48(5):1267–81. doi:10.1016/j.jpba.2008.09.020.
   PubMed Web of Science ®Google Scholar